respiratory
Lung cancer

Closing in on targeted therapy for lung SCC


Dr Clare Weeden is a researcher in the Stem Cells and Cancer Division at the Walter and Eliza Hall Institute.

Read more

Australian researchers have discovered a better biomarker for identifying which patients with lung squamous cell carcinoma will respond to fibroblast growth factor receptor (FGFR) inhibitors. The study using patient-derived xenografts in laboratory models of the disease, found high levels of FGFR1 in tumour RNA were a better predictor of response to FGFR tyrosine kinase inhibitors than the current ...

Already a member?

Enter your email to keep reading.


OR